Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: A molecular basis for melatonin-induced oncostatic effects

Journal of Pineal Research

Volumn 39, Issue 1, 2005, Pages 12-20

  Cini, Grazia ^a   Neri, Bruno ^a   Pacini, Alessandra ^a   Cesati, Valentina ^a   Sassoli, Chiara ^a   Quattrone, Silvia ^a   D'Apolito, Maria ^b   Fazio, Antonina ^b   Scapagnini, Giovanni ^c   Provenzani, Alessandro ^a   Quattrone, Alessandro ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

Author keywords

17 estradiol; cAMP responsive element; Cell cycle; Cyclin D1; MCF 7 cells; Melatonin

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIN D1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MELATONIN; PROTEIN C JUN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER ADJUVANT THERAPY; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DNA MICROARRAY; DNA RESPONSIVE ELEMENT; GENE OVEREXPRESSION; GENE TRANSCRIPTION INHIBITION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REPORTER GENE; TRANSCRIPTION REGULATION;

ADJUVANTS, IMMUNOLOGIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELATONIN; TRANSCRIPTION, GENETIC;

EID: 22044439575     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2004.00206.x     Document Type: Article

References (40)

1. ARENDT J. Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 2003; 15:427-431.
2. PARRY BL. Jet lag: minimizing it's effects with critically timed bright light and melatonin administration. J Mol Microbiol Biotechnol 2002; 4:463-466.
3. KARASEK M, REITER RJ, CARDINALI DP, PAWLIKOWSKI M. Future of melatonin as a therapeutic agent. Neuroendocrinol Lett 2002; 23(Suppl. 1):118-121.
4. BARTSCH C, BARTSCH H, KARASEK M. Melatonin in clinical oncology. Neuroendocrinol Lett 2002; 23(Suppl. 1):30-38.
5. VIJAYALAXMI TCR jr, THOMAS CR Jr, REITER RJ, HERMAN TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20:2575-2601.
6. COS S, SANCHEZ-BARCELO EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21:133-170.
7. COS S, SANCHEZ-BARCELO EJ. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 2000; 15:637-647.
8. COS S, FERNANDEZ R, GUEZMES A, SANCHEZ-BARCELO EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58:4383-4390.
9. TAMARKIN L, DANFORTH D, LICHTER A et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982; 216:1003-1005.
10. BARTSCH C, BARTSCH H, FUCHS U, LIPPERT TH, BELLMANN O, GUPTA D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 1989; 64:426-433.
11. BLASK DE, HILL SM, ORSTEAD KM, MASSA JS. Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis. J Neural Transm 1986; 67:125-138.
12. COS S, SANCHEZ-BARCELO EJ. Melatonin inhibition of MCF-7 human breast-cancer cells growth: influence of cell proliferation rate. Cancer Lett 1995; 93:207-212.
13. COS S, FERNANDEZ F, SANCHEZ-BARCELO EJ. Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci 1996; 58:2447-2453.
14. COS S, RECIO J, SANCHEZ-BARCELO EJ. Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci 1996; 58:811-816.
15. HILL SM, BLASK DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48:6121-6126.
16. PANZER A, LOTTERING ML, BIANCHI P, GLENCROSS DK, STARK JH, SEEGERS JC. Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett 1998; 122:17-23.
17. RAM PT, YUAN L, DAI J et al. Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. J Pineal Res 2000; 28:210-218.
18. COS S, BLASK DE, LEMUS-WILSON A, HILL AB. Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J Pineal Res 1991; 10:36-42.
19. KIEFER T, RAM PT, YUAN L, HILL SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002; 71:37-45.
20. GARCIA JJ, REITER RJ, ORTIZ GG et al. Melatonin enhances tamoxifen's ability to prevent the reduction in microsomal membrane fluidity induced by lipid peroxidation. J Membr Biol 1998; 162:59-65.
21. KOTHARI A, BORGES A, INGLE A, KOTHARI L. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-N-methylurea-induced rat mammary tumors. Cancer Lett 1997; 111:59-66.
22. RATO AG, PEDRERO JG, MARTINEZ MA, DEL RIO B, LAZO PS, RAMOS S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999; 13:857-868.
23. VAN DER BURG B, SELM-MILTENBURG AJ, DE LAAT SW, VAN ZOELEN EJ. Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endocrinol 1989; 64:223-228.
24. CAVAILLES V, AUGEREAU P, GARCIA M, ROCHEFORT H. Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. Nucleic Acids Res 1988; 16:1903-1919.
25. GRONEMEYER H. Transcription activation by estrogen and progesterone receptors. Annu Rev Genet 1991; 25:89-123.
26. HILL SM, SPRIGGS LL, SIMON MA, MURAOKA H, BLASK DE. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 1992; 64:249-256.
27. CLARKE R, DICKSON RB, LIPPMAN ME. Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 1992; 12:1-23.
28. AUGEREAU P, MIRALLES F, CAVAILLES V, GAUDELET C, PARKER M, ROCHEFORT H. Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol 1994; 8:693-703.
29. WEISZ A, ROSALES R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res 1990; 18:5097-5106.
30. STACK G, KUMAR V, GREEN S et al. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. Cancer Treat Res 1988; 40:185-206.
31. BARNES DM, GILLETT CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998; 52:1-15.
32. SICINSKI P, DONAHER JL, PARKER SB et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 82:621-630.
33. BUCKLEY MF, SWEENEY KJ, HAMILTON JA et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8:2127-2133.
34. ALTUCCI L, ADDEO R, CICATIELLO L et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996; 12:2315-2324.
35. WILCKEN NR, PRALL OW, MUSGROVE EA, SUTHERLAND RL. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 1997; 3:849-854.
36. OESTERREICH S, ZHANG P, GULER RL et al. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001; 61:5771-5777.
37. SABBAH M, COURILLEAU D, MESTER J, REDEUILH G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA 1999; 96:11217-11222.
38. LISSONI P, CRISPINO S, BARNI S et al. Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology 1990; 47:275-277.
39. STEINHILBER D, BRUNGS M, WERZ O et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 1995; 270:7037-7040.
40. WEISZ A, BRESCIANI F (1993). Estrogen regulation of protooncogenes coding for nuclear proteins. Crit Rev Oncog, 1993; 4:361-388.